ClinicalTrials.gg
CompletedNCT05726318REDUCTIONUpdated Aug 27, 2025Results posted

Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women

A Phase 4 interventional study of Antibiotics in UTI, sponsored by Megan Bradley. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Megan Bradley · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Study summary

To evaluate the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection symptoms in older women and the adherence to study procedures.

Read the detailed description

To evaluate A) the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection (UTI) symptoms in older women and B) the adherence to study procedures. We will recruit and enroll women with a history of recurrent UTI (rUTI) from the Women's Center for Bladder and Pelvic Health and the University of Pittsburgh's Clinical and Translational Science Institute (CTSI) Pitt+Me® Research Registry. Once enrolled and randomized, women will be followed for a total of 28 days to document both clinical resolution at day 7 from symptom onset and adverse events. H1) Enrolling a total of 70 subjects in \<1 year (at least 10% of eligible patients) will demonstrate feasibility of recruitment and H2) Documenting at least 70% patient compliance with study procedures will confirm patient adherence to study protocol. Exploratory Aim: To explore the safety of a culture-directed UTI treatment strategy and preliminary secondary outcomes of assigned treatments. H1) There will be an overall low number of adverse events and H2) Preliminary outcome data will help power future trial.

02

Conditions studied

  • UTI
03

In context

Lead sponsor

Megan Bradley is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female biologic Sex
  • Age ≥65 years old
  • History of recurrent UTI per patient report of greater than 2 UTIs in the last 6 months or 3 UTIs in the last year
  • Patient reported UTI defined as:

    • Dysuria, increased urinary urgency/frequency and/or suprapubic pain

Exclusion criteria

Exclusion Criteria:

  • Male biologic sex
  • Age \<65 years old
  • History of augmentation cystoplasty or cystectomy
  • Currently performing clean intermittent self-catheterization
  • Current indwelling foley catheter
  • Urinary tract instrumentation (i.e., cystourethroscopy, foley catheter placement) in the last 30 days
  • Undergoing treatment for
  • History of either confirmed or patient reported pyelonephritis and/or urosepsis
  • Cirrhosis and/or end stage liver disease
  • Chronic kidney disease with most recent estimated \<50 ml/min
  • Dementia and/or currently reside in skilled nursing facility
  • Current high-dose chronic (>20mg/day of prednisone)
  • Previous solid organ transplant
  • Provider concern for pyelonephritis and/or sepsis (i.e., fevers)
  • Unwilling or unable to comply with study procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Other
    Culture-directed antibiotic

    Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.

    Drug: Antibiotics

  • Active comparator
    Empiric antibiotic

    Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current Infectious Disease Society of American (IDSA) guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.

    Drug: Antibiotics

Interventions

  • DrugAntibiotics

    Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days

06

What researchers measure

Primary outcomes

  1. Eligible Subjects That Were Enrolled in the Study

    Number and proportion of eligible subjects that were enrolled in the study

    Time frame: Through study completion, an average of 17.5 months

Secondary outcomes

  1. Number of Persons That Were Screened for Participation

    Overall number of persons that were screened for participation

    Time frame: Through study completion, an average of 17.5 months

  2. Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria

    Number of person screened who met include/exclusion criteria divided by number participants screened

    Time frame: 30 days

  3. Proportion of Persons Screened Who Declined Participation or Were Ineligible

    Number of person screened who declined or were ineligible divided by number participants screened

    Time frame: 30 days

  4. Proportion of Participants Enrolled Who Completed the Study

    Number of persons enrolled who completed the study (at least one follow-up questionnaire and completed the day 28 questionnaire) divided by number participants enrolled

    Time frame: 30 days

  5. Monthly Enrollment Rate

    number of participants that were enrolled each month

    Time frame: Through study completion, an average of 17.5 months

  6. Proportion of Enrolled Participants That Completed All Study Procedures

    Number of persons enrolled who completed all study procedures (completed all 4 follow-up questionnaires) divided by number participants enrolled

    Time frame: 30 days

  7. Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms

    Number of persons enrolled who took alternative agents for management of symptoms divided by number participants enrolled

    Time frame: 30 days

  8. Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms

    Number of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms divided by the number of participants in the culture-directed arm

    Time frame: 30 days

  9. Proportion of Enrolled Participants That Completed Electronic Surveys

    Number of persons enrolled who completed all electronic surveys divided by number participants enrolled

    Time frame: 30 days

Other outcomes

  1. Clinical Success at 14 Days

    Score of \<1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.

    Time frame: 14 days

07

Results

Posted Aug 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneCulture-directed AntibioticEmpiric Antibiotic
Started3535
Completed3131
Not completed44

Outcome measures

PrimaryEligible Subjects That Were Enrolled in the Study

Number and proportion of eligible subjects that were enrolled in the study

Time frame:
Through study completion, an average of 17.5 months
Reported as:
Count of participants · Participants
Eligible Subjects That Were Enrolled in the Study
ParticipantsOverall Number and Proportion of Eligible Subjects That Were Enrolled in the Study
Eligible Subjects That Were Enrolled in the Study70
SecondaryNumber of Persons That Were Screened for Participation

Overall number of persons that were screened for participation

Time frame:
Through study completion, an average of 17.5 months
Reported as:
Count of participants · Participants
Number of Persons That Were Screened for Participation
ParticipantsNumber of Subjects That Were Screened for Participation
Number of Persons That Were Screened for Participation131
SecondaryProportion of Persons Screened Who Met Inclusion/Exclusion Criteria

Number of person screened who met include/exclusion criteria divided by number participants screened

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria
ParticipantsNumber and Proportion of Subjects Screened Who Met Inclusion/Exclusion Criteria
Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria103
SecondaryProportion of Persons Screened Who Declined Participation or Were Ineligible

Number of person screened who declined or were ineligible divided by number participants screened

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Persons Screened Who Declined Participation or Were Ineligible
ParticipantsProportion of Persons Screened Who Declined Participation or Were Ineligible
Proportion of Persons Screened Who Declined Participation or Were Ineligible43
SecondaryProportion of Participants Enrolled Who Completed the Study

Number of persons enrolled who completed the study (at least one follow-up questionnaire and completed the day 28 questionnaire) divided by number participants enrolled

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Participants Enrolled Who Completed the Study
ParticipantsCulture-directed AntibioticEmpiric Antibiotic
Proportion of Participants Enrolled Who Completed the Study3031
Statistical analysis
  • Culture-directed Antibiotic vs Empiric Antibiotic · Chi-squared · p = .78
SecondaryMonthly Enrollment Rate

number of participants that were enrolled each month

Time frame:
Through study completion, an average of 17.5 months
Reported as:
Median · participants enrolled per month
Monthly Enrollment Rate
participants enrolled per monthMonthly Enrollment Rate
Monthly Enrollment Rate4 (2 to 5)
SecondaryProportion of Enrolled Participants That Completed All Study Procedures

Number of persons enrolled who completed all study procedures (completed all 4 follow-up questionnaires) divided by number participants enrolled

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Enrolled Participants That Completed All Study Procedures
ParticipantsCulture-directed AntibioticEmpiric Antibiotics
Proportion of Enrolled Participants That Completed All Study Procedures3031
Statistical analysis
  • Culture-directed Antibiotic vs Empiric Antibiotics · Chi-squared · p = .78
SecondaryProportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms

Number of persons enrolled who took alternative agents for management of symptoms divided by number participants enrolled

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms
ParticipantsCulture-directed AntibioticEmpiric Antibiotic
Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms1610
Statistical analysis
  • Culture-directed Antibiotic vs Empiric Antibiotic · Chi-squared · p = .68
SecondaryProportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms

Number of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms divided by the number of participants in the culture-directed arm

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms
ParticipantsCulture-directed Arm
Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms1
SecondaryProportion of Enrolled Participants That Completed Electronic Surveys

Number of persons enrolled who completed all electronic surveys divided by number participants enrolled

Time frame:
30 days
Reported as:
Count of participants · Participants
Proportion of Enrolled Participants That Completed Electronic Surveys
ParticipantsCulture-directed AntibioticEmpiric Antibiotics
Proportion of Enrolled Participants That Completed Electronic Surveys3031
Statistical analysis
  • Culture-directed Antibiotic vs Empiric Antibiotics · Chi-squared · p = .78
Other pre-specifiedClinical Success at 14 Days

Score of \<1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.

Time frame:
14 days
Reported as:
Count of participants · Participants
Clinical Success at 14 Days
ParticipantsCulture-directed AntibioticEmpiric Antibiotic
Clinical Success at 14 Days1912
Statistical analysis
  • Culture-directed Antibiotic vs Empiric Antibiotic · Chi-squared · p = 0.13

Adverse events

Collected over 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Culture-directed Antibiotic0/35 (0%)0/35 (0%)5/35 (14.3%)
Empiric Antibiotic0/35 (0%)0/35 (0%)0/35 (0%)
Most frequent other events
Most frequent other events
EventCulture-directed AntibioticEmpiric Antibiotic
DiarrheaGastrointestinal disorders5/350/35
Nausea/Vomiting SymptomsGastrointestinal disorders3/350/35
RashSkin and subcutaneous tissue disorders0/350/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Culture-directed AntibioticEmpiric AntibioticTotal
Mean74.1 ± 7.175.7 ± 6.874.9 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Culture-directed AntibioticEmpiric AntibioticTotal
Female353570
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Culture-directed AntibioticEmpiric AntibioticTotal
Hispanic or Latino011
Not Hispanic or Latino353469
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Culture-directed AntibioticEmpiric AntibioticTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White353469
More than one race000
Unknown or Not Reported000
Number of Participants with Diabetes Mellitus
Number of Participants with Diabetes Mellitus(Participants)Culture-directed AntibioticEmpiric AntibioticTotal
Count of participants5611
BMI
BMI(kg/m^2)Culture-directed AntibioticEmpiric AntibioticTotal
Mean30.5 ± 7.628.5 ± 6.129.5 ± 6.9
Pelvic Floor Distress Inventory-20
Pelvic Floor Distress Inventory-20(units on a scale)Culture-directed AntibioticEmpiric AntibioticTotal
Mean137.9 ± 59.9146.0 ± 68.0142.0 ± 63.7
08

Study locations

1 site
  • Magee Women's Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Will review each request individually and work with University of Pittsburgh Research Agreements to share.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 1 year after completion

Access criteria: unknown at this time

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Aug 2024, 17 months.

Results were first posted in Aug 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2023
First posted
Feb 13, 2023
StartActual
Feb 17, 2023
Primary completionActual
Aug 2, 2024
CompletionActual
Aug 2, 2024
Results first posted
Aug 27, 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05726318
Lead sponsor
Megan Bradley
Responsible party
Megan Bradley (Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Feb 13, 2023
Start date
Feb 17, 2023
Primary completion
Aug 2, 2024
Completion
Aug 2, 2024
Results posted
Aug 27, 2025
Last update
Aug 27, 2025

Study contacts

Megan S Bradley
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion